First Patient Dosed in Ph 1 Trial of RMC-5127 in patients with RAS G12V–mutated solid tumors February 1, 2026
Imfinzi perioperative regimen recommended for approval in the EU by CHMP for patients with early gastric and gastroesophageal cancers February 1, 2026
Continued Zenocutuzumab Treatment Beyond Progression Shows Benefit in Patients with NRG1+ Pancreatic Cancer and Cholangiocarcinoma from the eNRGy Trial January 18, 2026
RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat CRC January 18, 2026
Positive Follow-Up Data from Ph 2 Trial Shows Extended Long-Term OS Benefit with Elraglusib + Chemo for Metastatic Pancreatic Cancer January 18, 2026
Ph 1/2a Data of IMC002 Highlighted a Durable Complete Response Beyond 1 Year and a 66.7% ORR in Advanced GC/GEJ January 18, 2026
FDA grants Orphan Drug Designation Granted to NP-G2-044 for the Treatment of Pancreatic Cancer January 18, 2026
Data from Ph 1/2 trial of Multi-Antigen Targeted T cells in patients with pancreatic cancer announced January 11, 2026
BRAFTOVI® Regimen with Additional Chemo Backbone Increased Response Rates for Certain Patients with Metastatic CRC January 11, 2026
VYLOY™ (zolbetuximab) + Chemo Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses January 11, 2026
Strong Topline Ph 2 Results for DSP107 in Combination with Anti-PD-L1 Therapy in CRC Announced January 11, 2026
Ziihera (zanidatamab-hrii) Results in 1L HER2+ Locally Advanced or Metastatic GEA Announced Including 2+ Years Median OS Benefit January 11, 2026
64% OS At 12 Months Announced in 1L Pancreatic Cancer Patients Treated with Atebimetinib + mGnP January 11, 2026
Phase III Stage of the Ongoing Ph 2/3 Trial of Surufatinib – Camrelizumab combo for 1L Pancreatic Ductal Adenocarcinoma Initiated January 4, 2026
NMPA approves TABOSUN + TYVYT combo for the neoadjuvant treatment of patients with stage IIB-III resectable MSI-H/dMMR colon cancer January 4, 2026
12-Month OS Data from Ph 2a Trial of Atebimetinib + mGnP in 1L Pancreatic Cancer Patients to be announced on Jan 7, 2026 December 30, 2025
NDA for savolitinib for locally advanced/metastatic GC/GEJ adenocarcinoma patients with MET amplification accepted and granted priority review by the China NMPA December 30, 2025
Positive Scientific Advice from EMA on the Design of a Ph 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Announced December 30, 2025
First pancreatic cancer patient in global Ph 3 registrational trial, MAPKeeper 301, to be dosed in mid-2026 December 30, 2025
Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic CRC Announced December 22, 2025
